Description
Systemic bevacizumab to treat refractory bleeding in hereditary haemorrhagic telangiectasia: A single centre case series
€3.03
Systemic bevacizumab to treat refractory bleeding in hereditary haemorrhagic telangiectasia: A single centre case series
Notifications